|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
23
|
|
pubmed:dateCreated |
2010-12-8
|
|
pubmed:abstractText |
The cancer stem cell hypothesis predicts that standard prostate cancer monotherapy eliminates bulk tumor cells but not a tumor-initiating cell population, eventually leading to relapse. Many studies have sought to determine the underlying differences between bulk tumor and cancer stem cells.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/AC133 antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD44,
http://linkedlifedata.com/resource/pubmed/chemical/Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/NVP BEZ235,
http://linkedlifedata.com/resource/pubmed/chemical/PTEN Phosphohydrolase,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/Quinolines
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AimoneLindsey JLJ,
pubmed-author:ChoCharles YCY,
pubmed-author:DubrovskaAnnaA,
pubmed-author:ElliottJimmyJ,
pubmed-author:Garcia-EcheverriaCarlosC,
pubmed-author:KimSungeunS,
pubmed-author:MairaSauveur-MichelSM,
pubmed-author:ReddyVenkateshwar AVA,
pubmed-author:SalamoneRichard JRJ,
pubmed-author:SchultzPeter GPG,
pubmed-author:WalkerJohn RJR,
pubmed-author:WatsonJamesJ
|
|
pubmed:copyrightInfo |
©2010 AACR.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5692-702
|
|
pubmed:meshHeading |
pubmed-meshheading:21138868-Animals,
pubmed-meshheading:21138868-Antigens, CD,
pubmed-meshheading:21138868-Antigens, CD44,
pubmed-meshheading:21138868-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21138868-Carcinoma,
pubmed-meshheading:21138868-Cell Differentiation,
pubmed-meshheading:21138868-Cell Line, Tumor,
pubmed-meshheading:21138868-Cell Proliferation,
pubmed-meshheading:21138868-Cell Survival,
pubmed-meshheading:21138868-Drug Delivery Systems,
pubmed-meshheading:21138868-Glycoproteins,
pubmed-meshheading:21138868-Humans,
pubmed-meshheading:21138868-Imidazoles,
pubmed-meshheading:21138868-Male,
pubmed-meshheading:21138868-Mice,
pubmed-meshheading:21138868-Mice, Inbred C57BL,
pubmed-meshheading:21138868-Mice, Inbred NOD,
pubmed-meshheading:21138868-Mice, SCID,
pubmed-meshheading:21138868-Neoplastic Stem Cells,
pubmed-meshheading:21138868-PTEN Phosphohydrolase,
pubmed-meshheading:21138868-Peptides,
pubmed-meshheading:21138868-Prostatic Neoplasms,
pubmed-meshheading:21138868-Quinolines,
pubmed-meshheading:21138868-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma.
|
|
pubmed:affiliation |
The Scripps Research Institute, La Jolla, California 92037, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
